Stapled peptides offer a new approach to fighting brain-targeting viral infections | Research

The takeaway

Peptide stapling—a chemical modification that stabilizes peptide structure—enhances the antiviral potential of peptides against neurotropic viruses like HSV and influenza by improving stability, bioavailability, and target binding.

Stapling solves peptide drug limitations
Chemical stapling of alpha-helices improves stability, bioavailability, and cellular penetration of antiviral peptides against neurotropic viruses

What the researchers found

Peptide stapling via hydrocarbon staples, lactam bridges, and metal-coordination bonds enhances peptide stability, bioavailability, cellular penetration, and target binding affinity for antiviral applications against neurotropic viruses including HSV and influenza.

Why it matters

Neurotropic viral infections cause devastating diseases with limited treatment options. Stapled peptides could overcome the pharmacological limitations of natural antiviral peptides, creating a new class of drugs for brain-targeting viruses that resist current therapies.

The numbers in context

Reviews stapling techniques for peptides targeting HSV, VZV, HIV, poliovirus, enteroviruses, parechovirus, West Nile virus, and Japanese encephalitis virus.

How the study worked

Narrative review of stapling techniques and their application to antiviral peptide development, focusing on neurotropic viral targets.

Who was studied

Not applicable (peptide chemistry review)

What this study cannot tell us

Review of early-stage research; most stapled antiviral peptides are in preclinical development. No clinical trial data available. Manufacturing complexity and cost of stapled peptides may limit scalability.

How to read the evidence

Narrative review of preclinical research. Provides comprehensive overview of the technology but no clinical evidence for antiviral stapled peptides specifically.

When this study was published

Published in 2025; covers latest advances in stapled peptide antiviral development.

The bigger picture

Peptide stapling represents a broader advance in peptide drug design that could transform multiple therapeutic areas. By solving the fundamental stability and bioavailability problems of peptide drugs, stapling technology may unlock the therapeutic potential of peptides that were previously too fragile for clinical use.

Questions still open

Which stapling technique offers the best balance of efficacy, stability, and manufacturability for antiviral applications?
Can stapled peptides cross the blood-brain barrier effectively to treat neurotropic infections?
How do stapled antiviral peptides compare to small molecule antivirals in terms of resistance development?

Common questions

What is peptide stapling?

Peptide stapling is a chemical modification that locks a peptide into its active three-dimensional shape (usually an alpha-helix) by adding a covalent bridge between amino acid side chains. This makes the peptide more resistant to degradation, better able to enter cells, and more effective at binding its target.

Why are brain viruses hard to treat?

Neurotropic viruses hide in the nervous system where they are protected by the blood-brain barrier, limiting drug access. They also resist many conventional antivirals. Stapled peptides could overcome these challenges by being more stable in the body and potentially crossing the blood-brain barrier more effectively.

Read the original research

Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections.

Microbial biotechnology, 18(9), e70221

View on PubMed ↗Publisher’s paper ↗

Citation

Patil, Sanskruti; Rahangdale, Rakesh; Pasupuleti, Mukesh; Santhoshkumar, Puttur; Hariharapura, Raghu Chandrashekar. (2025). Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections.. Microbial biotechnology, 18(9), e70221. https://doi.org/10.1111/1751-7915.70221